Summary of Celcuity Conference Call Company Overview - **Company**: Celcuity (NasdaqCM:CELC) - **Focus**: Development of a platform to isolate and quantify the activity of live patient tumor cells to identify responsive patients for targeted therapies, particularly in the PI3K space with the drug gedatolisib, a pan-PI3K/mTOR inhibitor [7][8] Key Points and Arguments Clinical Development - **Phase 3 Studies**: Completed one phase three study and has another upcoming report in the second line study for breast cancer, along with a first line study in progress [7][8] - **Efficacy of Gedatolisib**: - Demonstrated unprecedented efficacy in the second line setting with a median progression-free survival (PFS) of 9.3 months compared to 2 months for fulvestrant, with a hazard ratio of 0.24 [34] - Early phase data showed a median PFS of 14.5 months in a cohort of patients with PIK3CA mutations, indicating potential for significant clinical relevance [36][37] - **Targeting the PAM Pathway**: Gedatolisib is believed to effectively target the PAM pathway, which has been suboptimally targeted by other drugs, leading to modest efficacy in a subset of patients [14][15] Market Landscape - **Current Treatments**: The current standard of care for HR-positive breast cancer patients is yielding limited results, with existing therapies like fulvestrant and AI not showing significant improvements [25][26] - **Impact of Competitors**: Recent failures of other oral SERDs in clinical trials provide clarity on treatment regimens and highlight the potential for gedatolisib to fill the gap in treatment efficacy [27][28] Future Studies and Expectations - **Upcoming Data**: Expected to report data on the mutant population by the end of the current quarter or next quarter, with a focus on achieving statistically significant results [36][37] - **Frontline Study**: A phase 3 study targeting HR-positive, treatment-naive patients is in progress, with a safety run-in evaluating gedatolisib combined with ribociclib [55][57] Commercial Strategy - **Sales Force Preparation**: The company is preparing to build a sales force, targeting around 90 representatives, to effectively reach healthcare providers [63][64] - **Market Access**: The intravenous formulation of gedatolisib is expected to facilitate easier reimbursement pathways compared to oral drugs, enhancing market access [67] International Expansion - **Regulatory Strategy**: Plans to submit a Marketing Authorization Application (MAA) in Europe following the mutation data submission to the FDA, with a focus on major markets including the EU and Japan [81][82] Additional Insights - **Prostate Cancer Program**: Gedatolisib is also being evaluated in combination with darolutamide for prostate cancer, showing promising early results [70][71] - **Potential for Other Tumor Types**: There is interest in exploring gedatolisib's efficacy in endometrial cancer, although the landscape is complicated by the use of PD-1 drugs [74] Intellectual Property - **Patent Exclusivity**: The company expects patent term exclusivity through 2042 based on dosing patents, which are critical for optimizing treatment outcomes [76][77] This summary encapsulates the key points discussed during the Celcuity conference call, highlighting the company's strategic direction, clinical developments, and market positioning.

Core Insights - Kazia Therapeutics provided a clinical update on its Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy for late-stage metastatic triple-negative breast cancer (TNBC) [1] Clinical Highlights - The Phase 1b trial is a multi-center, open-label, randomized study initiated in June 2025, focusing on the safety, tolerability, and preliminary clinical activity of paxalisib in advanced breast cancer patients [4] - Three patients with metastatic TNBC have shown meaningful clinical responses, including two partial responses and one confirmed complete metabolic response [2][9] Patient Responses - Patient 1, a 61-year-old female, achieved a partial response after nine cycles of treatment with paxalisib, pembrolizumab, and chemotherapy [5] - Patient 2, a 47-year-old female, demonstrated a partial response with complete resolution of a target lung lesion after three treatment cycles [6] - Patient 3, a 44-year-old female, achieved a confirmed complete metabolic response after re-treatment with paxalisib and pembrolizumab [7] Safety and Tolerability - Paxalisib has been generally well tolerated, with approximately 75% of adverse events assessed as unlikely or unrelated to the drug [8] - Most adverse events were mild to moderate, with only one case of Grade 1 hyperglycemia reported [8] Future Plans - Kazia plans to activate two additional clinical sites by April 2026 and aims to enroll twelve TNBC patients by the end of 2026, with topline data expected in early 2027 [9] - The company is also exploring paxalisib in other breast cancer populations, including earlier-stage TNBC and hormone receptor-positive, HER2-negative breast cancer [10] Executive Commentary - Dr. John Friend, CEO of Kazia Therapeutics, expressed optimism about the preliminary results, highlighting the rarity of confirmed complete responses in metastatic TNBC and the potential of paxalisib to enhance existing immunotherapy regimens [11]